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Autoimmune diseases, including rheumatoid arthritis (RA) and systemic sclerosis (SSc) are
characterized by a strong genetic susceptibility from the Human Leucocyte Antigen (HLA)
locus. Additionally, disorders of epigenetic processes, in particular non-random X chromo-
some inactivation (XCI), have been reported in many female-predominant autoimmune dis-
eases. Here we test the hypothesis that women with RA or SSc who are strongly genetically
predisposed are less susceptible to XCI bias.
Methods
Using methylation sensitive genotyping of the androgen receptor (AR) gene, XCI profiles
were performed in peripheral blood mononuclear cells from 161 women with RA, 96 women
with SSc and 100 healthy women. HLA-DRB1 and DQB1 were genotyped. Presence of
specific autoantibodies was documented for patients. XCI skewing was defined as having a
ratio 80:20 of cells inactivating the same X chromosome.
Results
110 women with RA, 68 women with SSc, and 69 controls were informative for the AR poly-
morphism. Among them 40.9% of RA patients and 36.8% of SSc patients had skewed XCI
compared to 17.4% of healthy women (P = 0.002 and 0.018, respectively). Presence of RA-
susceptibility alleles coding for the “shared epitope” correlated with higher skewing among
RA patients (P = 0.002) and such correlation was not observed in other women, healthy or
with SSc. Presence of SSc-susceptibility alleles did not correlate with XCI patterns among
SSc patients.
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Conclusion
Data demonstrate XCI skewing in both RA and SSc compared to healthy women. Unex-
pectedly, skewed XCI occurs more often in women with RA carrying the shared epitope,
which usually reflects severe disease. This reinforces the view that loss of mosaicism in
peripheral blood may be a consequence of chronic autoimmunity.
Introduction
Female predominance in autoimmune diseases is remarkable as approximately 80% of patients
are women [1, 2]. Rheumatoid arthritis (RA), and systemic sclerosis (SSc) are both examples of
autoimmune diseases that follow this rule with women:men ratios going from 3:1 in RA to 11:1
in SSc [2]. RA and SSc are often characterized by the presence of autoantibodies in patients’
sera. The most specific autoantibodies in SSc are antitopoisomerase antibodies (ATA) and
anticentromere antibodies (ACA), which are respectively a hallmark of diffuse cutaneous SSc
and limited cutaneous SSc; the two clinical subtypes of the disease [3]. Autoantibodies encoun-
tered in RA are the rheumatoid factor (RF) and the highly specific anti-citrullinated protein
antibodies (ACPA) [4], and they can precede the clinical manifestation of RA by many years
[5, 6].
As in most autoimmune diseases, gene polymorphisms in the Human Leucocyte Antigen
(HLA) locus account for the highest genetic risk in the development of RA and SSc. In RA, sev-
eral HLA-DRB1 alleles (01:01, 01:02, 01:04, 04:01, 04:04, 04:05, 04:08, 10:01 and 14:02)
are implicated [7]. They code for a shared motif of five amino-acid sequence 70Q(or R)-K(or
R)-R-A-A74, the so-called shared epitope (SE), in the third hypervariable region of the DRβ1
molecule [8]. A parallel to the SE of RA can be made in SSc. Indeed, disease subtypes and auto-
antibody profiles are strongly associated withHLA-DRB and DQB alleles, such as DRB111,
08 (in European and African-American subjects) DRB501:01 (in linkage disequilibrium with
the Asian susceptibility allele DRB115:02), DQB103, 06, etc. [9–11]. Most DRB alleles associ-
ated with SSc have in common an amino-acid sequence 67F-L-E-D-R71 on their β chain. Simi-
larly, most DQB susceptibility alleles code for a common 71T-R-A-E-L-D-T77 motif on their β
chain, and both motifs are often associated with an ATA producing SSc profile [11, 12].
It is likely that X-linked risk factors have a role to play in disease onset and progression.
Skewed X chromosome inactivation (XCI) is well established in peripheral blood cells from
women with autoimmune thyroiditis and SSc [13–16]. Only one report shows such a bias in
RA from a North African population [17] and one in juvenile idiopathic arthritis [18].
XCI is an epigenetic dosage compensation mechanism in female mammalian cells where
either the paternally-derived or the maternally-derived X chromosome is randomly silenced in
early embryonic life [19]. Skewing then represents a deviation from the 50:50 ratio and is arbi-
trarily defined, often as a pattern were 80% or more ( 80:20) of the cells inactivate the same X
chromosome [20]. This deviation is thought to be the result of i) genetic factors directly
involved in the process of XCI, ii) genetic defects (mutations, rearrangements,. . .) on the X
chromosome leading to a selective process, iii) tendency towards monoclonal expansion of
cells related to aging, or iv) pure chance, due to the stochastic nature of the choice of which X
chromosome to inactivate in the early stages of embryogenesis [21, 22].
The most accepted explanation to biased XCI in autoimmunity is a mechanism through
which loss of mosaicism has the potential to make X-linked self-antigens escape presentation
in the thymus, leading to the breakdown of tolerance and causing the development of autoim-
mune diseases [23]. Although this view lacks supporting evidence and remains to be
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confirmed, one would expect that women with autoimmune disease who are strongly geneti-
cally predisposed are less susceptible to skewed XCI. This is also reinforced by the observation
that HLA genes’ contribution to the RA or SSc risk is substantially greater in men than in
women [24, 25]. Indeed, men do not have the epigenetic possibility of biased XCI and are more
genetically predisposed than women, when affected [24, 25]. We then hypothesize that women
with RA and SSc would have less skewed XCI patterns if carrying one of the strongest risk pre-
dictors in both diseases: susceptibility in the HLA class II locus.
Methods
Participants’ characteristics
Among the 357 female subjects included in the study, a total of 110 women with RA (median
age and interquartile range (IQR): 58 [51–66] years), 68 women with SSc (55 [48–54] years),
and 69 healthy women (52 [46–58] years) were informative for the XCI assay and were consid-
ered in subsequent analyses. Among the 69 control women, 65 were Caucasian (94.2%), 3 from
Sub-Saharan African Ancestry, and 1 Asian. Patients with RA were recruited from the rheuma-
tology service of Marseille’s hospitals (France) and satisfied the 2010 revised criteria of the
American College of Rheumatology and the European League Against Rheumatism [26]. Of
them, 108 were Caucasian (98.2%), 1 African, and 1 Asian. Patients with SSc were enrolled in
collaboration with 5 French hospitals from Paris, Marseille and Lille, and met the requirements
of LeRoy [27]. Among them, 55 were Caucasian (80.8%), 8 were African, and 5 Asian. Median
age, with IQR, at the onset of disease was 48 [41–57] and 46 [37–55] years, and median disease
duration was 6 [1–17] and 6 [4–12] years, for RA and SSc respectively. The selection criterion
for healthy controls was no symptoms or familial history of autoimmune disorder.
To evaluate XCI patterns and the SE in autoimmune disease other than RA, women with
SSc were tested. As women with SSc who carry the RA-specific SE are rare, we added women
with SSc previously described in a North American study, who had comparable XCI pattern
with our French SSc cohort to increase statistical power [16]. Among the 94 additional SSc
women informative in the XCI assay, HLA-DRB1 and DQB1 genotyping was retrospectively
obtained for 92 of them.
Positivity for ACPA was used to define mainstream RA because of its well-recognized diag-
nostic and predictive value [4]. Therefore, all selected patients with RA were ACPA-positive.
Positivity for ACPA was obtained from patients’ clinical files for 17 out of 110 RA patients. For
the remaining 93 patients, ACPA were detected by anti-CCP2 Enzyme-linked immuno-sor-
bent assay (ELISA) (Immunoscan RA, Euro-Diagnostica, Arnhem, The Netherlands). Positiv-
ity was defined by a cut-off value of 25 Units/mL at a dilution of 1:50 of patients’ plasma.
Median ACPA titration, with IQR, was 528 [228–896] Units/mL.
For the French patients with SSc, autoantibody profiles (ATA, ACA) and patients’ disease
subtypes were obtained by reviewing medical records. Among them, 37 had the diffuse cutane-
ous form of the disease, with 24 of them being positive for ATA, and 31 had the limited cutane-
ous form, with 2 of them being positive for ATA and 20 for ACA. Thirty-six patients were
assessed for anti-RNA Pol III autoantibodies by Quanta Lite anti-RNAP III ELISA kit (INOVA
Diagnostics, San Diego, USA) following manufacturer’s recommendations, only one was posi-
tive (3%). Clinical characteristics and methods of DNA extraction and HLA genotyping for the
American SSc patients were described elsewhere [28].
Ethics statement
The study has received the approval of the ethics committee (Comité de Protection des Per-
sonnes Sud-Méditerranée II, CPP) and is registered at the INSERM under the Biomedical
X Chromosome Inactivation and Genetic Risk in Autoimmunity
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Research Protocol number RBM-04-10 or as a collection under the number DC-2008-327. All
participants signed informed consent according to the Declaration of Helsinki [29].
PBMC and plasma isolation, and DNA extraction
Peripheral blood mononuclear cells (PBMCs) and plasma were isolated from 8 mL of whole
blood (drawn in EDTA or heparin vacutainer tubes) using Ficoll Histopaque 1077 (Sigma-
Aldrich, St Louis, MO, USA) gradient centrifugation. Plasma was stored at −80°C. Genomic
DNA was extracted from PBMCs with EZ1 DNA Tissue Kit (Qiagen, Hilden, Germany) using
a BioRobot EZ1 system (Qiagen, Hilden, Germany) according to the manufacturer’s instruc-
tions, and stored at −20°C.
HLA-DRB1 and HLA-DQB1 genotyping
HLA-DRB1 typing was carried out for all subjects at the Etablissement Français du Sang (Mar-
seille, France) and/or in our laboratory, using sequence-specific oligonucleotide (SSO) typing
kits (Dynal, Invitrogen, Carlsbad, CA, USA; SSO LABType, One Lambda Inc., CA, USA) for
generic typing and/or sequence-specific primer (SSP) typing kits (Olerup HLA-DRB104, Gen-
ovision, Vienna, Austria) for allelic typing. HLA-DQB1 typing was done for all subjects except
RA patients. SSO typing kits were used for this purpose (RELI SSO, Dynal, Invitrogen, Brom-
borough, Wirral, UK).
X chromosome inactivation assay
Genotyping of a polymorphic site in the human androgen receptor (AR) gene was performed
and quantified based on the use of radioactive α-33P-dCTP (NEN, Boston, MA, USA) to assess
the XCI patterns as previously described [13, 30]. DNA methylation occurs on the inactive X,
and prevents a methylation-sensitive HpaII restriction enzyme to cleave on its specific site
located on exon 1 of AR gene. When the genomic DNA is cleaved withHpaII prior to PCR,
only the methylated AR allele, which represents the inactive X-chromosome, is amplified. A
polymorphic CAG repeat located within the amplified region is used to distinguish between
the two alleles (Fig 1). For each patient and control the same polymerase chain reactions
(PCRs) was performed on two samples, with or without HpaII treatment. Male DNA with veri-
fied 46XY karyotype was used as control for complete digestion. Densitometric analysis of the
alleles was performed at least twice for each sample using the MultiAnalyst version 1.1 software
(Bio-rad, Hercules, California, USA). A corrected ratio was calculated by dividing the ratio of
the predigested sample (upper/lower allele) by the ratio of the non-predigested sample for nor-
malization of the ratios that were obtained from the densitometric analyses. The use of cor-
rected ratio compensates for preferential amplification of the shorter allele when the number of
PCR cycles increases [31]. A skewed population is defined when a cell population represents
80% or higher of one of the AR alleles (mosaicism ratio of 80:20) and extremely skewed
when mosaicism is at a ratio 90:10. It is noted that French and American patients with SSc
have been tested for XCI with the same methods.
Statistical analyses
A categorical approach was chosen to statistically analyze XCI data, in consistency with the his-
torical way of classifying XCI patterns into random, skewed, and extremely skewed. An r × c
Fisher’s exact test (r and c represent respectively a number of rows and a number of columns)
was applied in contingency analyses. This test gives exact P values and is particularly robust
when expected values in contingency tables are sparse [32]. When expected values were large
X Chromosome Inactivation and Genetic Risk in Autoimmunity
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( 5), the difference between exact and approximate P values would be minor and either Fish-
er’s exact or chi-square “Χ2” test were used (with Yates’ correction in case of 2 × 2 contingency
tables).
A continuous approach was also applied through the non-parametric two-sample Kolmogo-
rov–Smirnov (K–S) test. K–S is notably useful to test the equality of continuous probability dis-
tribution, and is sensitive to differences in both location and shape of the cumulative
distribution functions of two compared samples. Exact P values in K–S were computed to bet-
ter account for smaller sample sizes. Continuous correlation was assessed with the non-
parametric Spearman rank test. P values less than 0.05 were considered significant. Statistical
analyses were conducted using GraphPad Prism 5 software (La Jolla, CA, USA) STATA 14
(College Station, TX, USA), and the online tool “Statistics to Use” (Kirkman, T.W. http://www.
physics.csbsju.edu/stats/).
Results
Women with RA and women with SSc have more often a skewed XCI
pattern
Individuals for whom paternally-derived and maternally-derived AR gene alleles could not be
distinguished were not included in the analysis and considered as non-informative. XCI status
was informative for 110 of the 161 RA patients (68.3%), 69 of the 100 healthy women (69.0%),
and 68 of the 96 SSc patients (70.8%) from the present study, comparable to the reported
75.2% in the North American SSc patients [16].
Overall, XCI patterns significantly differed between patients and healthy controls. Skewed
patterns ( 80:20) were more frequent among women with RA or women with SSc when com-
pared to healthy women (respectively, 40.9% [45/110], 36.8% [25/68] versus 17.4% [12/69]). P
values were respectively 0.002 and 0.018 (Χ2 with Yates’ correction). This result would remain
significant with a Bonferroni correction (two comparisons).
Statistical differences were even more pronounced when comparing frequencies of
extremely skewed XCI patterns ( 90:10) between patients and controls. Indeed, 26.4% (29/
110) of RA women, 29.4% (20/68) of French SSc women had an extremely skewed pattern
Fig 1. Example of X chromosome inactivation status in 5 samples. Polymerase chain reaction products from the androgen receptor (AR) methylation
assay shows random X chromosome inactivation (50–79%) in samples A and C, and skewed X chromosome inactivation (80–89%) in sample E. Samples B
and D have a non-informative status. For each sample, DNA was either undigested (−) or digested (+) with the methylation-sensitive restriction enzyme
HpaII. Marker (331-bp and 242-bp) fragments are visible.
doi:10.1371/journal.pone.0158550.g001
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compared to only 2.9% (2/69) among healthy women (P = 0.00013 and 0.00007 respectively;
Χ2 with Yates’ correction; Fig 2).
When modeling XCI patterns through a continuous approach, probabilities of random XCI
patterns decreased and those of skewed XCI patterns increased significantly in women with
RA and SSc compared to healthy women (P = 0.013 and 0.009 respectively, K–S).
No statistical difference was observed in XCI patterns between RA and SSc patients
(P = 0.35; Χ2 test and P = 0.15, K–S).
Skewed XCI occurs more often with the presence of the SE among
women with RA
XCI patterns were evaluated with respect to the presence of genetic susceptibility in the HLA
locus. In the context of RA, the presence ofHLA-DRB1 alleles coding for the SE motif was ana-
lyzed in association with XCI patterns. Of the 247 women informative for XCI status, 235 were
HLA-DRB1 genotyped at the allelic level. The presence of the SE, as expected, was more frequent
among women with RA. Indeed, SE was present in double dose (SE+/+) in 20.8% (21/101) and
in single dose (SE+/−) in 51.5% (52/101) of RA patients, compared to only 7.2% (5/69) and
27.6% (19/69) respectively in healthy women, and only 3.1% (2/65) and 20% (13/65) respectively
in SSc patients from the present study.
Fig 2. Degrees of X chromosome inactivation (XCI) in healthy women (HW), women with rheumatoid arthritis (RA),
and womenwith systemic sclerosis (SSc) in the French cohort (Fr). Upper part: Proportional analysis with respect to the
three categories of XCI: Extreme skewing (90:10! 100:0), Medium skewing (80:20! 89:11), and Random (50:50! 79:21).
P values were from Χ2 with Yates’ correction. Lower part: Scatter plots showing a difference of the distribution of XCI patterns
in women with RA and SSc compared to HW (P = 0.013 and 0.009 respectively, Kolmogorov–Smirnov).
doi:10.1371/journal.pone.0158550.g002
X Chromosome Inactivation and Genetic Risk in Autoimmunity
PLOS ONE | DOI:10.1371/journal.pone.0158550 June 29, 2016 6 / 12
The prevalence of a skewed XCI was associated with the presence of the SE in women with
RA. The contingency matrix showed that skewed patterns were significantly more common
among women with RA when they had SE-positive alleles (r × c Fisher’s exact test, P = 0.002;
Table 1). Probability distribution of XCI patterns in women with RA revealed the most skewing
when they had a double dose of SE compared to both a single dose of SE or none (P = 0.045
and 0.008; K–S). This effect was not apparent for RA women with one dose of SE compared to
no SE (P = 0.294, K–S). On the other hand, with either categorical or continuous statistics, no
significant association of XCI patterns could be observed with the presence of the SE among
healthy women or among women with SSc, whether from our French cohort or from the
North American one. These two groups of SSc women were combined to increase statistical
power in the analysis and represented in Table 1. Such combination seemed appropriate after
verifying that XCI pattern did not differ between the French and American women with SSc
(P = 0.10, Χ2 test), as random, skewed, and extremely skewed patterns were present in 62
(66.0%), 15 (16.0%), and 17 (18.1%) of the 94 American patients assayed for XCI.
Susceptibility alleles specific to SSc were analyzed in comparison to XCI profiles. HLA-DR and
DQ genotyping was available for 158 of the 162 informative French and American SSc patients to
identify FLEDR-positiveDRB1 andDRB5 alleles and TRAELDT-positiveDQB1 alleles. No statisti-
cally significant association of their presence with XCI skewing could be observed in the French SSc
group, or the North American group (data not shown) or both combined (Table 1).
Table 1. Comparison of X chromosome inactivation patterns and the presence of HLA-susceptibility alleles.
N Random XCI (50:50 79:21) Medium skewing (80:20 89:11) Extreme skewing (90:10 100:0) P value†
SE* in RA
−/− 28 21 (75.0%) 4 (14.3%) 3 (10.7%)
+/− 52 29 (55.8%) 11 (21.1%) 12 (23.1%) 0.002
+/+ 21 9 (42.9%) 0 (0.0%) 12 (57.1%)
SE* in HW
−/− 45 38 (84.5%) 6 (13.3%) 1 (2.2%)
+/− 19 15 (78.9%) 4 (21.1%) 0 (0.0%) 0.29
+/+ 5 4 (80.0%) 0 (0.0%) 1 (20.0%)
SE* in SSc‡
−/− 106 68 (64.2%) 11 (10.4%) 27 (25.5%)
+/− 42 27 (64.3%) 8 (19.0%) 7 (16.7%) 0.56
+/+ 9 6 (66.7%) 1 (11.1%) 2 (22.2%)
67FLEDR71 in SSc‡
−/− 59 38 (64.4%) 10 (16.9%) 11 (18.6%)
+/− 72 45 (62.5%) 9 (12.5%) 18 (25.0%) 0.49
+/+ 27 19 (70.4%) 1 (3.7%) 7 (25.9%)
71TRAELDT77 in SSc‡
−/− 25 16 (64.0%) 3 (12.0%) 6 (24.0%)
+/− 74 44 (59.5%) 11 (14.9%) 19 (25.7%) 0.74
+/+ 59 42 (71.2%) 6 (10.2%) 11 (18.6%)
*SE represents the 70Q(R)K(R)RAA74 motif carried by “shared epitope”-positive HLA-DRB1 alleles that predispose to RA, but not to SSc. Therefore, SSc-
associated shared amino-acid motifs 67FLEDR71 (from some DRB1 and DRB5 alleles) and 71TRAELDT77 (from some DQB1 alleles) were considered as
additional controls in this context.
†r × c Fisher’s exact test.
‡Women with SSc described in this analysis are compiled results from French women and North American women. HW: healthy women; RA: women with
rheumatoid arthritis; SE: shared epitope; SSc: women with systemic sclerosis; XCI: X chromosome inactivation.
doi:10.1371/journal.pone.0158550.t001
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XCI patterns are not associated with age, disease duration, disease
subtype, treatments or presence of autoantibodies
In addition to genetic susceptibility, we proposed to analyze whether presence of autoantibod-
ies in plasma of patients, age, disease duration, subtype of disease (in the case of SSc) were cor-
related with XCI patterns. French and North American patients with SSc had similar XCI
profiles, and they were combined in Table 2 to increase statistical power.
Despite this, the subset analysis in Table 2 was susceptible to be underpowered, as sample
sizes tended to be small on many occasions. Age did not appear to have an effect on XCI in all
groups, and neither disease duration in women with RA and SSc. A correlation analysis
revealed Spearman R coefficients all between −0.02 and 0.11 (data not shown). XCI patterns
were not significantly associated (Fisher and K–S tests) with low or high ACPA titers among
women with RA, where high-positive ACPA was defined by a value superior to three times the
upper limit of a normal titer [26], or 3 × 25 Units/mL in this study. XCI patterns were not sig-
nificantly associated (Fisher and K–S tests) with a limited or diffuse cutaneous form of SSc, and
presence of ACA among women with SSc. Women with SSc positive for ATA had a tendency
to have more often a skewed XCI pattern, without reaching significance (P = 0.08, K–S test;
P = 0.06, 2 × 2 Fisher’s exact test). These negative results held for SSc whether analyzed from
our current study, replicated in the American study (data not shown), or both combined
(Table 2).
Women with RA who had skewed XCI had similar treatments as patients with random XCI.
Among patients with RA for whom we had treatment information, 64% of patients with biased
XCI (N = 28) were under anti-TNF treatments (etanercept and infliximab) versus 62% of
patients with unbiased XCI (N = 34). Other treatments were only methotrexate or only corti-
coids or both combined and were similarly found in both groups (respectively 36% and 38%).
Discussion
Many studies have shown an association between skewed XCI and autoimmunity [13–18], but
none had analyzed any correlation with genetic susceptibility, or other variables that character-
ize diseases. We show a higher prevalence of skewed XCI in peripheral blood cells of women
affected with RA and SSc compared to healthy women, in agreement with those previous stud-
ies. This prevalence is particularly remarkable when comparing extreme skewing in RA and
SSc patients versus controls. Furthermore, XCI patterns found in our group of healthy women
match those described in large cohorts of controls [33], supporting the idea that they corre-
spond to patterns in the general population.
Next, we found that women with RA were likelier to have skewed patterns when they car-
ried SE-positive alleles (P = 0.002). This result goes in the opposite direction of our initial
hypothesis, stating that if genetic and epigenetic factors both contribute to disease susceptibil-
ity, one would be more present when the other is lacking. Importantly, this association between
SE and skewing was not noticed among control women, whether healthy or with SSc. Contrary
to what was found in RA, analysis of SSc-specific HLA-susceptibility alleles, namely the
FLEDR-positive and TRAELDT-positive alleles, with skewed patterns among women with SSc
suggested that HLA predisposition in SSc and X chromosome mosaicism were unrelated.
Although we used Fisher’s exact test that gives exact P values, robust when numbers in con-
tingency tables are sparse, and computed exact P values when K–S test was used, we remained
limited in group sizes. As expected, there were few healthy women with extreme skewing
(N = 2) or healthy women and women with SSc who carry a double dose of the RA-specific SE
(N = 5 and 2, respectively). For better statistical power, we were able to combine our group of
women with SSc with a North American group previously described for XCI but never tested
X Chromosome Inactivation and Genetic Risk in Autoimmunity
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for HLA association with skewing [16]. Whether both SSc groups were analyzed together or sepa-
rately, theHLA-DRB1 and DQB1 susceptibility alleles remained not associated with XCI patterns
and, importantly, women with SSc who carried the RA-specific SE were not preferentially
skewed. This reinforces our observation that the influence of RA-specific HLA-susceptibility
Table 2. Contingency analyses of X chromosome inactivation patterns in regard to various subjects’ characteristics.
N Random XCI (50:50 79:21) Medium skewing (80:20 89:11) Extreme skewing (90:10 100:0) P value†
Healthy women
Age (years)*
36–46 21 17 (81.0%) 4 (19.0%) 0 (0.0%)
47–57 28 22 (78.6%) 5 (17.8%) 1 (3.6%) 0.56
58–69 20 18 (90.0%) 1 (5.0%) 1 (5.0%)
RA women
Age (years)*
27–44 17 12 (70.6%) 1 (5.9%) 4 (23.5%)
45–62 51 34 (66.7%) 7 (13.7%) 10 (19.6%) 0.34
63–80 36 17 (47.2%) 7 (19.5%) 12 (33.3%)
Disease duration (years)
0–9 63 40 (63.5%) 12 (19.0%) 11 (17.5%)
10–19 21 14 (66.7%) 1 (4.8%) 6 (28.5%) 0.12
 20 24 11 (45.8%) 3 (12.5%) 10 (41.7%)
ACPA titers (U/mL)
25–75 (low-positive) 9 7 (77.8%) 0 (0.0%) 2 (22.2%)
 76 (high-positive) 84 47 (55.9%) 13 (15.5%) 24 (28.6%) 0.43
SSc women‡
Age (years)*
18–38 31 23 (74.2%) 4 (12.9%) 4 (12.9%)
39–59 91 56 (61.5%) 13 (14.3%) 22 (24.2%) 0.51
60–80 39 25 (64.1%) 3 (7.7%) 11 (28.2%)
Disease duration (years)
0–9 129 83 (64.3%) 16 (12.4%) 30 (23.3%)
10–19 20 11 (55.0%) 4 (20.0%) 5 (25.0%) 0.50
 20 12 10 (83.3%) 0 (0.0%) 2 (16.7%)
Disease type
Limited cutaneous 58 40 (69.0%) 6 (10.3%) 12 (20.7%)
Diffuse cutaneous 101 64 (63.4%) 12 (11.9%) 25 (24.8%) 0.82
ATA§
Positive 50 27 (54.0%) 7 (14.0%) 16 (32.0%)
Negative 89 63 (70.8%) 9 (10.1%) 17 (19.1%) 0.14¶
ACA§
Positive 28 17 (60.7%) 5 (17.9%) 6 (21.4%)
Negative 95 63 (66.3%) 7 (7.4%) 25 (26.3%) 0.28
*Range of years was equally divided by 3, accordingly forming 3 groups.
†r × c Fisher’s exact test.
‡SSc women from both current and American studies are represented here in the analyses.
§ATA and ACA information were missing from 23 and 39 cases out of the 94 SSc from the American study.
¶When analyzing ATA-positive versus negative and random XCI versus skewed XCI ( 80:20) in a 2 × 2 approach, P value was 0.06 (Fisher’s exact) or 0.08
(Kolmogorov–Smirnov’s exact) for continuous XCI distribution. ACA: anticentromere antibody; ACPA: anti-citrullinated protein antibody; ATA:
antitopoisomerase antibody; RA: rheumatoid arthritis; SSc: systemic sclerosis; XCI: X chromosome inactivation.
doi:10.1371/journal.pone.0158550.t002
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alleles on XCI patterns is limited to RA, and similar influence is not seen in SSc even with SSc-
specific HLA-susceptibility alleles.
A skewed XCI has been proposed as an X-linked risk factor in the development of autoim-
munity [13–18]. In this perspective, our findings may suggest that skewed inactivation of the X
chromosome and polymorphisms of HLA genes on chromosome 6 are synergic risk factors in
RA. If this is true however, a skewed XCI would also be more prevalent in subjects carrying the
SE, even without RA. This assumption remains unlikely, as it does not appear to be the case in
our group of healthy controls or in the group of women with another autoimmune condition,
i.e. SSc, for which the SE does not confer susceptibility.
Our data demonstrate a correlation between skewing and the presence of the SE, the main
genetic susceptibility marker associated with RA pathogenesis. The SE is also considered a marker
of severe disease activity, cartilage erosion and bone destruction, regardless of therapy [34–36].
Accordingly, a model can be proposed where skewed XCI is a consequence of the severity of the
autoimmune condition, a result of an accelerated rate of turnover in selected clones of immune
cells. One can suspect the involvement of CD4+ T cells and antigen presenting cells, on the
grounds that the SE is part of HLA class II molecules. Interestingly, XCI bias has been previously
shown associated with a deregulated Foxp3 expression, an X-linked molecule, on CD4+ T regula-
tory cells from patients with SSc [37]. As a result of this proposed model, skewing is expected to
increase with disease duration. A tendency towards more frequent XCI skewing already appears
in our data among RA patients with the longest disease duration, although statistically not signifi-
cant (P = 0.12, Table 2). In SSc on the other hand, disease severity often depends on the clinical
subtypes and, ultimately, is associated with autoantibody profiles [3, 38]. Of the two classical
autoantibodies in SSc, ATA predict severe outcomes and higher mortality rates [3, 38]. In this
case also, XCI bias is expected to occur more often in SSc patients when ATA are present. Our
data show a tendency towards more frequent skewing among ATA-positive SSc patients, without
being statistically significant. It is possible that tendencies not reaching statistical significance are
the consequence of lack of power, due to smaller sample sizes in the sub-groups analyses of
Table 2. Our proposed model thus merits further confirmation on larger RA and SSc cohorts.
In summary, the present study demonstrates the association of biased XCI patterns with RA
and SSc in a French population, comes in agreement with previous findings on XCI in autoim-
munity, and presents the first evidence of a disease-specific association between loss of mosaicism
and HLA susceptibility (in RA). In this direction, data are robust, dually controlled against both
healthy individuals and individuals with another autoimmune disease. The association of a
skewed pattern with the presence of the SE in RA is less in favor of skewing as a contributor to
autoimmunity. Rather, skewing as a consequence of cell division in chronic disease seems to be
the most plausible explanation accounting for our findings. Next steps should address a number
of important questions, including the immuno-phenotype of cells most likely to express skewed
patterns, whether certain X-linked polymorphisms contribute to clonal-expansion-derived XCI
bias, and to which extent the autoimmune environment influences such bias.
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